Q3 Earnings Forecast for TSE:MDP Issued By Raymond James

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Raymond James decreased their Q3 2025 EPS estimates for Medexus Pharmaceuticals in a research note issued on Tuesday, January 7th. Raymond James analyst M. Freeman now anticipates that the company will post earnings of ($0.03) per share for the quarter, down from their previous forecast of $0.01. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at $0.03 EPS and Q1 2026 earnings at $0.23 EPS.

Several other analysts have also recently issued reports on MDP. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Two research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, Medexus Pharmaceuticals presently has a consensus rating of “Strong Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Price Performance

Medexus Pharmaceuticals stock opened at C$4.04 on Friday. The firm’s 50 day moving average price is C$2.80 and its 200-day moving average price is C$2.54. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$4.24. The stock has a market cap of C$99.10 million, a P/E ratio of 80.80 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.